» Articles » PMID: 16197788

Predictors of Nonalcoholic Steatohepatitis (NASH) in Obese Patients Undergoing Gastric Bypass

Overview
Journal Obes Surg
Date 2005 Oct 4
PMID 16197788
Citations 59
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are conditions gaining increasing recognition in hepatology as a potential cause of cirrhosis and end-stage liver disease. Obesity is one of the main risk factors. The aims of this study were to determine the frequency of NAFLD in obese patients and to identify variables that predict NASH.

Methods: A prospective study was conducted of obese patients undergoing gastric bypass over a 20-month period. Assessment included liver function tests and evaluation of insulin resistance with the homeostatic model assessment (HOMA-IR). Liver biopsy was performed in all patients at the time of surgery. Clinical and biochemical variables were analyzed using a multivariate analysis to identify independent predictors of NASH.

Results: 127 consecutive patients were included (62% female, 38% male, mean age 40+/-11 years, mean body mass index 42+/-6 kg/m(2)). Arterial hypertension was present in 52 patients (41%) and type 2 diabetes in 18 (14%). NAFLD was confirmed in 80 patients (63%), 47 (37%) had simple steatosis, and 33 (26%) had NASH. Cirrhosis was found in 2 patients corresponding to 1.6% of the total population. On multivariate analysis, AST >31 (IU/L) (OR 3.38, CI 1.17-9.8) and HOMA-IR >5.8 (OR 4.18, CI 1.39-12.49) independently predicted NASH.

Conclusions: NAFLD is highly prevalent in morbidly obese patients. A high proportion of these patients exhibit NASH on histological examination. Insulin resistance represents the main predictor of NASH.

Citing Articles

Comprehensive Cross-Sectional Study of the Triglyceride Glucose Index, Organophosphate Pesticide Exposure, and Cardiovascular Diseases: A Machine Learning Integrated Approach.

Wang X, Tian M, Shen Z, Tian K, Fei Y, Cheng Y Toxics. 2025; 13(2).

PMID: 39997933 PMC: 11860532. DOI: 10.3390/toxics13020118.


Prevalence and Correlates of Probable Nonalcoholic Steatohepatitis (NASH) in Pars Cohort Study.

Nakhostin-Ansari A, Oskouie I, Aghajani R, Khadembashiri M, Ahmadi M, Gandomkar A Arch Iran Med. 2024; 27(11):598-605.

PMID: 39534993 PMC: 11558611. DOI: 10.34172/aim.30020.


Non-alcoholic fatty liver disease in obese subjects as related to increasing insulin resistance and deteriorating glucose control: Three years of follow-up from a longitudinal survey.

Forst T, Botz I, Berse M, Voswinkel S, Strempler M, Baumann S J Diabetes Metab Disord. 2024; 23(1):999-1006.

PMID: 38932817 PMC: 11196428. DOI: 10.1007/s40200-023-01378-z.


Sleeve Gastrectomy Reduces the Need for Liver Transplantation in Patients with Obesity and Non-Alcoholic Steatohepatitis: a Predictive Model.

Rouhi A, Castle R, Hoeltzel G, Williams N, Dumon K, Baimas-George M Obes Surg. 2024; 34(4):1224-1231.

PMID: 38379059 DOI: 10.1007/s11695-024-07102-x.


Expanding Pharmacists' Role in the Management of Non-Alcoholic Fatty Liver Disease.

Syed-Abdul M Pharmacy (Basel). 2023; 11(5).

PMID: 37736923 PMC: 10514885. DOI: 10.3390/pharmacy11050151.